In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 4, 1997, Pages 763-766

  Pfaller, M A ^a   Messer, S A ^a   Coffman, S ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA; CANDIDA PARAPSILOSIS; FUNGICIDAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE;

EID: 0030896916     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.4.763     Document Type: Article

References (14)

1. Current, W. L., C. J. Boylan, and P. P. Raab. 1993. Anti-Pneumocystis activity of LY303366 and other echinocandin B analogs, abstr. 368, p. 186. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. Gordee, R., J. Farmer, J. Flokowitsch, and P. Haeber. 1993. In vitro anti-fungal activity of LY303366, a new antifungal agent derived from echinocandin B, abstr. 360, p. 185. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Gordee, R. S., D. J. Zeckner, L. F. Ellis, A. L. Thakker, and L. C. Howard. 1984. In vitro and in vivo anti-Candida activity and toxicology of LY121019. J. Antibiot. 37:1054-1065.
4. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing of yeasts: tentative standard. M27-T. National Committee for Clinical Laboratory Standards, Wayne, Pa.
5. Pfaller, M. A., T. Gerarden, M. Yu, and R. P. Wenzel. 1989. Influence of in vitro susceptibility testing conditions on the anti-candidal activity of LY121019. Diagn. Microbiol. Infect. Dis. 11:1-9.
6. Pfaller, M. A., M. Bale, B. Buschelman, M. Lancaster, A. Espinel-Ingroff, J. H. Rex, M. G. Rinaldi, C. R. Cooper, and M. R. McGinnis. 1995. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J. Clin. Microbiol. 33:1104-1107.
7. Raab, P., D. Zeckner, B. Boyll, C. Boylan, and W. Current. 1994. LY303366; comparison of activity in murine models of Aspergillus fumigatus infection, abstr. F167, p. 252. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
8. Rex, J. H., M. A. Pfaller, M. Lancaster, F. C. Odds, A. Bolmström, and M. G. Rinaldi. 1996. Quality control guidelines for National Committee for Clinical Laboratory Standards-recommended broth macrodilution testing of ketoconazole and itraconazole. J. Clin. Microbiol. 34:816-817.
9. Tang, J., T. R. Parr, Jr., W. Turner, M. DeBono, L. LaGrandeur, F. Burkhardt, M. Rodriquez, M. Zweifel, J. Nissen, and K. Clingerman. 1993. LY303366: a noncompetitive inhibitor of (1,3)-β-D-glucan synthases from Candida albicans and Aspergillus fumigatus, abstr. 367, p. 186. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
10. Warren, N. G., and K. C. Hazen. 1995. Candida, Cryptococcus, and other yeasts of medical importance, p. 723-737. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, D.C.
11. Zeckner, D., T. Butler, C. Boylan, B. Boyll, Y. Lin, P. Raab, J. Schmidtke, and W. Current. 1993. LY303366, activity in a murine systemic candidiasis model, abstr. 365, p. 186. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
12. Zeckner, D., T. Butler, C. Boylan, B. Boyll, Y. Lin, P. Raab, J. Schmidtke, and W. Current. 1993. LY303366, activity against systemic aspergillosis and histoplasmosis in murine models, abstr. 364, p. 186. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
13. Zeckner, D., T. Butler, C. Boylan, B. Boyll, P. Raab, and W. Current. 1994. LY303366, activity in a rat mucocutaneous vaginal candidiasis model, abstr. F169, p. 252. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
14. Zornes, L., R. Stratford, M. Novilla, D. Turner, C. Boylan, B. Boyll, T. Butler, Y. Lin, D. Zeckner, W. Turner, and W. Current. 1993 Single dose IV bolus and oral administration pharmacokinetics of LY301366, a new lipopeptide antifungal agent related to echinocandin B, in female Lewis rats and beagle dogs, abstr. 370, p. 187. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.